Prediabetes / Hospital Operations6 min read

Prediabetes Follow-Up Program for Saudi Hospitals: Turning a Lab Result into a Managed Pathway

By

A prediabetes follow-up program for a Saudi hospital identifies patients from their lab results, enrols them in a registry, schedules repeat glucose or HbA1c testing, delivers lifestyle support in Arabic and English, and flags anyone who progresses to diabetes. Without it, a prediabetes result is often a one-off note that nobody owns.

Key takeaways

  • The gap is follow-through. In a Riyadh primary care chart review of 92 patients followed for three years, 76.08% remained prediabetic, 16.4% returned to normal glycaemia and 7.6% progressed to diabetes.
  • Prevalence is high: a 2025 systematic review of Saudi studies documented a high pooled prevalence of prediabetes in adults, markedly higher in males.
  • Knowledge and process gaps exist: a survey of 155 Saudi primary care physicians found gaps contributing to underscreening and undertreatment.
  • Attrition is the operational risk: in an 18-month Riyadh lifestyle trial, only 28 participants completed the full study, which shows why recall and engagement need design.
  • A hospital programme needs lab-triggered enrolment, a registry, risk-tiered recall, lifestyle touchpoints and a clear handoff to the diabetes pathway.
Illustrative glucose result and registry connecting recall to hospital follow-up
On this page

Why prediabetes follow-up fails quietly

Prediabetes rarely causes symptoms, so no complaint brings the patient back. The result sits in a lab report, the physician may or may not discuss it, and the next test depends on the patient remembering.

The Saudi data is consistent with that picture. A retrospective chart review at King Abdulaziz Medical City primary care centres in Riyadh (Alateeq et al., Cureus 2020) followed 92 patients with prediabetes for three years. Most stayed in the prediabetic range; metformin use was not significant for the glycaemic outcome, and lifestyle changes were not tracked. The paper also cites an estimate that 25.5% of Saudis aged 30 or older live with prediabetes, a figure that should be checked against current national data before use.

On the clinician side, a 2022 survey of 155 primary care physicians in Saudi Arabia found significant knowledge gaps about prediabetes screening and treatment, contributing to underscreening and undertreatment. And a 2025 systematic review and meta-analysis of Saudi prevalence studies (2000 to 2024) documented a high pooled prevalence among adults, with a markedly higher prevalence among males.

This is a systems problem as much as a clinical one. A hospital that receives thousands of glucose and HbA1c results each month already holds the list of people who need a pathway. What is missing is the process that turns the list into contact.

What the evidence says about interventions

Two Riyadh studies show what a programme can and cannot promise:

  • A 6-month intensive one-on-one lifestyle intervention delivered in primary care to Saudi women with prediabetes and overweight or obesity improved glycaemic and cardiometabolic profile, according to the authors, who noted that no intensive programme of this type had previously been run for women at risk in Saudi primary care.
  • An 18-month randomised multicentre trial in Riyadh recruited Saudis aged 25 to 60 with prediabetes. Of the participants analysed at 12 months (158), only 28 completed the entire 18-month study. The trial's design is a useful reminder that retention is the main operational challenge.

Larger international trials report that intensive lifestyle programmes reduced diabetes incidence, and the Saudi trial reports cite this evidence. Whether a given hospital programme achieves similar results depends on intensity, population and retention, so it should be measured locally, with clinical review.

Designing the programme

A workable hospital design has six components.

  1. Lab-triggered enrolment. When a result meets the clinical definition set by your clinical lead, the patient is flagged for review and, with consent, enrolled in a prediabetes registry. This removes dependence on the ordering physician's follow-through.
  2. A registry with ownership. Each patient has a responsible clinic, a next-test date and a status: stable, regressed or progressed.
  3. Risk-tiered recall. The clinical team defines tiers, for example by additional risk factors, and the system applies different recall intervals and outreach intensity to each tier.
  4. Lifestyle touchpoints in the patient's language. Education and coaching in Arabic and English, through channels patients already use. Consider women-focused tracks and seasonal adjustments; see Ramadan medication and routine support.
  5. Progression handoff. A patient who crosses into the diabetes range moves to the diabetes pathway with the history attached. For that pathway, see remote patient monitoring for diabetes and hypertension.
  6. Closed-loop referral. When primary care and hospital services share patients, referrals need confirmation of receipt and outcome; see closed-loop referral tracking.

If your organisation already runs registries for other conditions, prediabetes can sit on the same foundation. See chronic disease registry software for Saudi hospitals. For pregnancy-related glucose follow-up, the pathway differs; see postpartum follow-up after gestational diabetes.

An illustrative scenario

Imagine a hospital group whose lab flags 40 new prediabetes-range results in a week across three branches. Today those results go back to ordering clinics as routine reports. In a programme, each flagged patient receives a consent-based invitation, a baseline education message and a re-test date; those who do not respond are called by a nurse educator; and the clinic lead reviews a list of overdue re-tests every week. This is a hypothetical scenario, not a customer case, and the numbers are illustrative only.

Metrics that show whether it works

  • Enrolment rate among flagged patients, and consent rate.
  • Re-test completion within the interval set by the clinical lead.
  • Status at 12 and 36 months: stable, regressed to normal, progressed to diabetes, lost to follow-up.
  • Attrition by touchpoint: where in the programme patients drop out.
  • Language, branch and gender breakdowns, to find who the programme is missing.

Report process measures separately from clinical outcomes, and have clinical outcome claims reviewed before external use.

Governance and procurement

Registries hold personal health data. Ask vendors about consent capture, role-based access across branches, hosting and Saudi privacy requirements, and confirm that clinical thresholds and recall rules are configurable by your clinical team.

How CareSync fits

CareSync Network supports multi-branch hospitals that want registries, recall workflows and dashboards on one patient record view, configured to their own protocols. A working session can start with one question: how many patients with a prediabetes result in the last 12 months have a documented re-test?

FAQ

How often should prediabetes be rechecked?

The interval is a clinical decision made by the treating clinician or hospital protocol, based on current Saudi and international guidance. A follow-up system stores the interval and makes sure the recall happens.

Does prediabetes go away?

In the Riyadh chart review of 92 patients followed for three years, 16.4% returned to normal glycaemia, 76.08% stayed in the prediabetic range and 7.6% progressed to diabetes. Individual outcomes depend on the patient and the clinical situation.

Who should follow patients with prediabetes: primary care or the hospital?

Both can. Many programmes are primary-care led with hospital support, and what matters is that someone owns the recall. Shared registries and closed-loop referrals help when patients move between settings.

Is metformin recommended for prediabetes?

That is a clinical decision. In the Riyadh chart review, metformin use was not significant for the glycaemic outcome, but the study was retrospective and not designed to settle the question. Your clinical lead should follow current guidance.

What is the biggest operational risk in a prediabetes programme?

Attrition. In an 18-month Riyadh randomised trial, only 28 participants completed the whole study, which is why recall, engagement channels and language matter.


Sources

Book a CareSync demo